Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03582046 · ClinicalTrials.gov registry record · NA
Targeting Abdominal Perfusion Pressure in Septic Shock
A NA study, sponsored by Potrero Medical.
- Terminated
- Registry status
- NA
- Development phase
- 12
- Enrollment target
NCT03582046: Clinical Trial NA study, sponsored by Potrero Medical.
NCT03582046 is a NA study that was terminated before completion, run by Potrero Medical. The registered enrollment target is 12 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03582046, a NA study, was terminated before completion, sponsored by Potrero Medical.
- TERMINATED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
Study Summary
A randomized control trial among patients with septic shock, studying the incidence, progression and recovery of AKI.
Primary Outcome
To study kidney function and recovery in patients with septic shock and elevated IAP as measured by timed creatinine clearance on calendar days 1-7 when targeting treatment to maintain APP ≥ 60 mmHg with a variable MAP target as compared to standard of care with a fixed MAP target. Creatinine clearance on calendar day 7 post-intervention or on day of ICU discharge, whichever is earliest, is the primary endpoint. Post hospital stay, subjects will have 30 day and 90 day follow up to check subject
Interventions
- DEVICE Abdominal Perfusion Pressure (APP)
- DEVICE Mean Arterial Pressure (MAP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2019-02-05 |
| Est. Completion | 2020-06-20 |
| Phase | NA |
Why NCT03582046 stopped before completion
NCT03582046 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Abdominal Perfusion Pressure (APP) is the first listed.
NCT03582046 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03582046 about?
NCT03582046 is a clinical study titled "Targeting Abdominal Perfusion Pressure in Septic Shock". A randomized control trial among patients with septic shock, studying the incidence, progression and recovery of AKI.
What is the current status of trial NCT03582046?
This trial is currently terminated. It is a NA study. The enrollment target is 12 participants. The study started on 2019-02-05. Estimated completion is 2020-06-20.
What interventions are being tested in trial NCT03582046?
The interventions under investigation include: Abdominal Perfusion Pressure (APP) (DEVICE), Mean Arterial Pressure (MAP) (DEVICE).
Who is sponsoring clinical trial NCT03582046?
This trial is sponsored by Potrero Medical, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03582046's enrollment target sits among peer trials
12 1913th of 2000 higher than 74 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI